• In early May 2026, BioMarin Pharmaceutical reported first-quarter revenue of US$766.21 million, modestly above the prior year, but net income and earnings per share fell as higher manufacturing and acquisition-related costs weighed on profitability.
• At the same time, the company sharply raised its full-year 2026 revenue guidance to a range of US$3.83 billion to US$3.93 billion, signaling management’s confidence despite the earnings pressure.
• Next, we’ll examine how BioMarin’s stronger revenue outlook but lower earnings guidance may reshape the existing investment narrative around margin expansion.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

BioMarin Pharmaceutical Investment Narrative Recap

To own BioMarin today, you need to believe that its rare disease portfolio, led by VOXZOGO and expanded through acquisitions like Amicus, can turn rising revenue into sustainably higher profits. The latest results complicate that story: first quarter revenue edged higher, but earnings and margins moved the wrong way as manufacturing and acquisition-related costs increased. For now, this mostly reinforces rather than changes the key near term catalyst of execution on VOXZOGO and Amicus, and the biggest risk around persistent margin pressure.

The raised full year 2026 revenue guidance to US$3.83 billion to US$3.93 billion is the announcement that best ties this quarter to the broader thesis. It points to stronger demand across core products, including enzyme therapies and VOXZOGO, even as integration and manufacturing costs weigh on earnings. How well BioMarin converts this higher anticipated sales base into improved profitability will be crucial for how investors reassess both the margin expansion story and the stock’s recent share price weakness.

Yet beneath the upgraded sales outlook, investors should still be alert to the possibility that higher ongoing R&D and integration spending could...

BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029.

Uncover how BioMarin Pharmaceutical's forecasts yield a $89.96 fair value, a 74% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue of about US$4.2 billion and earnings near US$1.4 billion by 2028, so this quarter’s higher sales but weaker margins may either support that bullish view or raise new questions, depending on how you weigh the cost risks and what you expect to happen next.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth just $89.54!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

No Opportunity In BioMarin Pharmaceutical?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.